Skip to main content
SpringerLink
Log in

The influence of hospitalisation on drug prescription in primary care – a large-scale follow-up study

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective To explore the influence of hospitalisation on the prescription of drugs in the primary care sector using prescription data of a major statutory health insurance (SHI) organisation, with a special focus on the so-called “Me-Too” drugs – in particular, 3-hydroxy-3-methyl-glutaryl (HMG) CoA reductase inhibitors (statins) and proton pump inhibitors (PPIs).

Methods A comprehensive outpatient drug prescription analysis was conducted on members of a SHI who had been hospitalised during the first 3 months of 2004. The number and costs of all prescriptions of 2426 patients during a 3-month period before admission and after discharge, respectively, were compared using Wilcoxon’s signed rank test. Data are shown in absolute and relative numbers as well as relative risks (RR) and their 95% confidence intervals (CIs).

Results The total number of prescriptions before hospitalisation and after discharge remained nearly the same, while the number of different active substances prescribed per patient decreased by 4%. However, overall costs increased after discharge by 15% due to the higher cost per prescription. Changes in medication affected nearly every patient (98.1%), and 60% had at least five changes. Of the substances prescribed to an individual before admission, 57% were cancelled after discharge, and 55% of all substances prescribed after discharge were novel prescriptions. Significantly more patients received a PPI or statin after hospitalisation (RR for a PPI: 1.27; 95% CI: 1.12 –1.45; RR for a statin: 1.16; 95% CI: 1.02–1.32). The increase in PPI medication was due to a 58% increase in the number of patients receiving pantoprazole, a “Me-Too” drug.

Conclusion Hospitalisation exerts a marked influence on drug therapy in ambulatory care, with a significant increase in the prescription of novel, on-patent drugs instead of less expensive alternatives.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Harder S, Fischer P, Krause-Schäfer M, Ostermann K, Helms G, Prinz H, Hahmann M, Baas H (2005) Structure and markers of appropriateness, quality and performance of drug treatment over a 1-year period after hospital discharge in a cohort of elderly patients with cardiovascular diseases from Germany. Eur J Clin Pharmacol 60:797–805

    Article  PubMed  Google Scholar 

  2. Himmel W, Tabache M, Kochen MM (1996) What happens to long-term medication when general practice patients are referred to hospital? Eur J Clin Pharmacol 50:253–257

    Article  PubMed  CAS  Google Scholar 

  3. Himmel W, Kochen MM, Sorns U, Hummers-Pradier E (2004) Drug changes at the interface between primary and secondary care. Int J Clin Pharmacol Ther 42:103–109

    PubMed  CAS  Google Scholar 

  4. Roth-Isigkeit A, Harder S (2005) Reporting the discharge medication in the discharge letter. An explorative survey of family doctors (in German). Med Klin 100:87–93

    Article  Google Scholar 

  5. Harder S, Thurmann P, Huber T, Rietbrock N (1991) Prescription of drugs not listed in a clinic’s pharmacopoeia: supervision by clinical pharmacologists. Eur J Clin Pharmacol 40:561–564

    PubMed  CAS  Google Scholar 

  6. Feely J, Chan R, McManus J, O’Shea B (1999) The influence of hospital-based prescribers on prescribing in general practice. Pharmacoeconomics 16:175–181

    Article  PubMed  CAS  Google Scholar 

  7. Garattini S (1997) Are me-too drugs justified? J Nephrol 10:283–294

    PubMed  CAS  Google Scholar 

  8. Goozner M (2004) The $800 million pill. The truth behind the cost of new drugs (chapter 8: “Me Too”). University of California Press, Berkeley, Calif., London. Available at: http://www.ucpress.edu/books/pages/10083/10083.ch08.html (last accessed 2007/01/15)

  9. Head Associations of Health Insurance Funds (2006) Pharmaceutical Index of the Statutory Health Insurance (GKV-Arzneimittel-Schnellinformation, GAmSi). Essen. Available at: http://www.gamsi.de/dateien/GAmSiBundesbericht_2006_12.pdf (last accessed 2007/05/02)

  10. Beers MH, Dang J, Hasegawa J, Tamai IY (1989) Influence of hospitalization on drug therapy in the elderly. J Am Geriatr Soc 37:679–683

    PubMed  CAS  Google Scholar 

  11. Cochrane RA, Mandal AR, Ledger-Scott M, Walker R (1992) Changes in drug treatment after discharge from hospital in geriatric patients. BMJ 305:694–696

    PubMed  CAS  Google Scholar 

  12. Parente F, Cucino C, Gallus S, Bargiggia S, Greco S, Pastore L, Bianchi Porro G (2003) Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Aliment Pharmacol Ther 17:1503–1506

    Article  PubMed  CAS  Google Scholar 

  13. Schroder-Bernhardi D, Dietlein G (2002) Lipid-lowering therapy: do hospitals influence the prescribing behavior of general practitioners? Int J Clin Pharmacol Ther 40:317–321

    PubMed  CAS  Google Scholar 

  14. Weltermann B, Martin C, Adl S, Kuching A, Korbonits G, Hopp HW (1997) Prescribing practice for beta blockers at patient discharge to ambulatory care. A health care economic evaluation in a cardiology patient sample with special reference to drug budgeting (in German). Gesundheitswesen 59:258–261

    PubMed  CAS  Google Scholar 

  15. Pharmacy Price Schedule (German), ABDATA Pharma-Daten-Service, Eschborn, Germany

  16. WHO Collaborating Centre for Drug Statistics Methodology (2006). ATC/DDD Index 2006. Available at: http://www.whocc.no/atcddd/indexdatabase (last accessed 2007/01/15)

  17. Adl S, Weltermann BM, Kuching A, Martin C, Korbonits G, Hopp HW (2001) Difficulties in the transfer of drug therapy from inpatient to ambulatory treatment (in German). Gesundheitswesen 63:597–601

    Article  PubMed  CAS  Google Scholar 

  18. Hach I, Maywald U, Meusel D, Konig JU, Kirch W (2005) Continuity of long-term medication use after surgical hospital stay. Eur J Clin Pharmacol 61:433–438

    Article  PubMed  CAS  Google Scholar 

  19. Bundesgesetzblatt (2003) Gesetz zur Modernisierung der gesetzlichen Krankenversicherung. Teil I G 5702, nr. 55. Bonn, Bundesgesetzblatt, pp 2190–2258

  20. McDonagh MS, Carson S (2005) Drug Class Review on Proton Pump Inhibitors. Final Report. Oregon Health & Science University, Portland, Ore.

  21. Jones MI, Greenfield SM, Jowett S, Bradley CP, Seal R (2001) Proton pump inhibitors: a study of GPs’ prescribing. Fam Pract 18:333–338

    Article  PubMed  CAS  Google Scholar 

  22. Mat Saad AZ, Collins N, Lobo MM, O’Connor HJ (2005). Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract 59:31–34

    Article  PubMed  CAS  Google Scholar 

  23. Dai C, Stafford RS, Alexander GC (2005) National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med 165:158–160

    Article  Google Scholar 

  24. EMEA (European Medicines Agency). EMEA statement following withdrawal of Vioxx (rofecoxib) Doc. Ref: EMEA/97949/2004 Available at: http://www.emea.eu.int/htms/hotpress/d9794904.htm (last accessed 2007/ 01/15)

  25. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S et al. (2003) European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 10:S1–S10

    Google Scholar 

  26. The Institute of Quality and Economy in Healthcare (2006) Evaluation of the effects of statins (with particular consideration of atorvastatin (in German), ver 1.0. Institute of Quality and Economy in Healthcare, Cologne. Available at: http://www.iqwig.de/download/Nutzenbewertung_Statine.pdf (last accessed 2007/01/15)

  27. Simmenroth-Nayda A, Hummers-Pradier E, Ledig T, Jansen R, Niebling W, Bjerre LM, Kochen MM, Himmel W (2006) Prescription of generic drugs in general practice. Results of a survey of general practitioners (in German). Med Klin 101:705–710

    Article  Google Scholar 

  28. Schnipper J, Kirwin J, Cotugno M, Wahlstrom SA, Brown BA, Tarvin E et al. (2006) Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med 166:565–571

    Google Scholar 

  29. Duerden M, Walley T (1999) Prescribing at the interface between primary and secondary care in the UK. Towards joint formularies? Pharmacoeconomics 15:435–443

    Article  PubMed  CAS  Google Scholar 

  30. Hakansson A, Andersson H, Cars H, Melander A (2001) Prescribing, prescription costs and adherence to formulary committee recommendations: long-term differences between physicians in public and private care. Eur J Clin Pharmacol 57:65–70

    Article  PubMed  CAS  Google Scholar 

  31. Wolzt M, Ohrenberger G, Reichardt B (2003) Cost reduction with project based prescription of generic ACE inhibitors. Wien Klin Wochenschr 115:23–28

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

We are indebted to the AOK Mecklenburg-Vorpommern for the permission to perform this study with special thanks to Michael Hewelt for his valuable support.

Author information

Authors and Affiliations

  1. Medical Review Board of the Statutory Health Insurance Funds Mecklenburg-Vorpommern, Lessingstr. 31, 19059, Schwerin, Germany

    Thomas Grimmsmann & Ulrike Schwabe

  2. Department of General Practice/Family Medicine, University of Göttingen, Göttingen, Germany

    Wolfgang Himmel

Authors
  1. Thomas Grimmsmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrike Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wolfgang Himmel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Grimmsmann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grimmsmann, T., Schwabe, U. & Himmel, W. The influence of hospitalisation on drug prescription in primary care – a large-scale follow-up study. Eur J Clin Pharmacol 63, 783–790 (2007). https://doi.org/10.1007/s00228-007-0325-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-007-0325-1

Keywords

Search

Navigation